Australia Infectious Disease Market Outlook to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995
Buy Report

Published: March 30, 2020 Report Code: GDMECC4978DB-ST

Select Item

GlobalData’s “Australia Infectious Disease Market Outlook to 2025” is a comprehensive databook report, covering key market data on the Australia Infectious Disease market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Chlamydia Trachomatis Tests, Clostridium difficile Tests, Cytomegalovirus (CMV) Tests, Hepatitis Tests, Human Immunodeficiency Virus (HIV) Tests, Human Papilloma Virus (HPV) Tests, Human T-Lymphotropic Virus (HTLV) Tests, Multi-parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs, Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs), Mycobacterium Tuberculosis Tests, Neisseria Gonorrhoeae Tests and Treponema pallidum Tests.

The Australia Infectious Disease Market report provides key information and data on:
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2015 to 2025.
• 2018 company share and distribution share data for Infectious Disease Market.
• Global corporate-level profiles of key companies operating within the Australia Infectious Disease Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

Australia Infectious Disease Tests is segmented as follows:

• Chlamydia Trachomatis Tests

• Clostridium difficile Tests

• Cytomegalovirus (CMV) Tests

• Hepatitis Tests

• Human Immunodeficiency Virus (HIV) Tests

• Human Papilloma Virus (HPV) Tests

• Human T-Lymphotropic Virus (HTLV) Tests

• Multi-parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs

• Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs)

• Mycobacterium Tuberculosis Tests

• Neisseria Gonorrhoeae Tests

• Treponema pallidum Tests

Reasons to Buy

Key Reasons to Purchase – The Australia Infectious Disease Market report helps you to develop:

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Key companies covered in the “Australia Infectious Disease Market Outlook to 2025” report:
• Abbott Laboratories
• Siemens Healthineers AG
• F. Hoffmann-La Roche Ltd

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Infectious Disease Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 9

3 Infectious Disease Market, Australia 16

3.1 Infectious Disease Market, Australia, Revenue ($m), 2015-2025 16

3.1.1 Chlamydia Trachomatis Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 21

3.1.2 Clostridium difficile Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 23

3.1.3 Cytomegalovirus (CMV) Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 25

3.1.4 Hepatitis Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 27

3.1.5 Human Immunodeficiency Virus (HIV) Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 29

3.1.6 Human Papilloma Virus (HPV) Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 32

3.1.7 Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 34

3.1.8 Mycobacterium Tuberculosis Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 36

3.1.9 Neisseria Gonorrhoeae Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 38

3.1.10 Treponema pallidum Tests Market, Australia, Revenue ($m), by Segment, 2015-2025 40

3.2 Infectious Disease Market, Australia, Volume (Units), 2015-2025 43

3.2.1 Chlamydia Trachomatis Tests Market, Australia, Volume (Units), by Segment, 2015-2025 48

3.2.2 Clostridium difficile Tests Market, Australia, Volume (Units), by Segment, 2015-2025 50

3.2.3 Cytomegalovirus (CMV) Tests Market, Australia, Volume (Units), by Segment, 2015-2025 53

3.2.4 Hepatitis Tests Market, Australia, Volume (Units), by Segment, 2015-2025 55

3.2.5 Human Immunodeficiency Virus (HIV) Tests Market, Australia, Volume (Units), by Segment, 2015-2025 57

3.2.6 Human Papilloma Virus (HPV) Tests Market, Australia, Volume (Units), by Segment, 2015-2025 60

3.2.7 Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Volume (Units), by Segment, 2015-2025 62

3.2.8 Mycobacterium Tuberculosis Tests Market, Australia, Volume (Units), by Segment, 2015-2025 64

3.2.9 Neisseria Gonorrhoeae Tests Market, Australia, Volume (Units), by Segment, 2015-2025 66

3.2.10 Treponema pallidum Tests Market, Australia, Volume (Units), by Segment, 2015-2025 68

3.3 Infectious Disease Market, Australia, Average Price ($), 2015-2025 71

3.4 Infectious Disease Market, Australia, Distribution Share by Revenue ($m), 2018 77

3.5 Infectious Disease Market, Australia, Company Share by Revenue ($m), 2018 78

4 Overview of Key Companies in Australia, Infectious Disease Market 80

4.1 Abbott Laboratories 80

4.1.1 Company Overview 80

4.2 F. Hoffmann-La Roche Ltd 80

4.2.1 Company Overview 80

4.3 Siemens Healthineers AG 80

4.3.1 Company Overview 80

4.4 Hologic Inc 81

4.4.1 Company Overview 81

4.5 Danaher Corp 81

4.5.1 Company Overview 81

4.6 Qiagen NV 81

4.6.1 Company Overview 81

4.7 Becton Dickinson and Co 81

4.7.1 Company Overview 81

4.8 Grifols SA 82

4.8.1 Company Overview 82

5 Infectious Disease Market Pipeline Products 83

6 Financial Deals Landscape 86

6.1 Equity Offerings 86

6.1.1 Genetic Signatures Raises USD1.7 Million in Share Purchase Plan 86

6.1.2 Genetic Signatures to Raise USD13.4 Million in Second Tranche of Private Placement of Shares 87

6.1.3 Genetic Signatures Raises USD10.4 Million in First Tranche of Private Placement of Shares 89

6.1.4 Anteo Diagnostics Raises USD1.79 Million in Rights Offering 91

6.1.5 Ellume Plans to Raise Funds in IPO of Shares 92

6.2 Venture Financing 93

6.2.1 SpeeDx Raises USD10 Million in Venture Financing 93

6.2.2 Ellume Raises USD3.4 Million in Financing Round 94

6.2.3 SpeeDx Raises Additional USD5 Million in Series A Financing 95

7 Recent Developments 96

7.1 Corporate Communications 96

7.1.1 Oct 28, 2019: Genetic Signature: Non-Executive Director retirement 96

7.1.2 Aug 20, 2019: Genera Biosystems announces resignation of executive director and company secretary 96

7.1.3 Jul 29, 2019: Anteo Diagnostics: CEO appointment 96

7.1.4 Jul 22, 2019: Anteo Diagnostics: Management changes 97

7.1.5 Jul 11, 2019: Genera Biosystems: Appointment of Executive Director 97

7.1.6 Jul 02, 2019: Genera Biosystems: Resignation of non-executive director 98

7.1.7 May 27, 2019: Gordon Ballantyne, Managing Director and Chief Executive Officer to depart healthscope 98

7.1.8 May 09, 2019: Genera Biosystems: Resignation Of Non-execuitve Director 99

7.1.9 Apr 15, 2019: Anteo Diagnostics: Strengthens executive team with CEO appointment 99

7.1.10 Apr 12, 2019: Genera Biosystems: Key executive appointment & capital raising update 100

7.1.11 Mar 04, 2019: Genetic Signatures: Change of Company Secretary 101

7.1.12 Feb 28, 2019: Anteo Diagnostics: Appointment of CFO and company secretary 101

7.2 Financial Announcements 101

7.2.1 Jul 31, 2019: Genera Biosystems: Quarterly cash flow and business update 101

7.2.2 Jul 25, 2019: Genetic Signatures: Quarterly Activities Report – 30 June 2019 102

7.2.3 May 01, 2019: Genera Biosystems: Appendix 4C quarterly cash flow and capital raising update 103

7.3 Legal And Regulatory 104

7.3.1 Mar 04, 2019: Genetic Signatures: Change of Registered Address 104

7.4 Other Significant Developments 104

7.4.1 Oct 30, 2019: Anteo delivers a quarter of progressive strategy execution 104

7.4.2 Oct 28, 2019: Genetic Signatures: Quarterly activities report – 30 September 2019 104

7.4.3 Oct 28, 2019: Genetic Signatures: A$2.1m R&D rebate received 106

7.4.4 Oct 02, 2019: Double Bond Pharma signed a distribution agreement with Zoono 106

7.4.5 Aug 09, 2019: New diagnostic method for fungal infections could combat a major global health risk 106

7.4.6 Apr 29, 2019: Genetic Signatures: Quarterly activities report – 31 March 2019 107

7.4.7 Apr 08, 2019: UniSA startup releases AI app to detect Parkinson’s disease 107

7.4.8 Feb 21, 2019: Anteo makes solid progress with GeneoDx partnership 109

8 Appendix 110

8.1 Research Methodology 111

8.1.1 Coverage 111

8.1.2 Secondary Research 111

8.1.3 Primary Research 112

8.1.4 Market Modeling and Forecasting 113

8.1.5 Company Share Analysis 114

8.1.6 Distribution Share Analysis 115

8.1.7 Benchmarking 115

8.2 GlobalData Consulting 115

8.3 Contact Us 116

8.4 Disclaimer 116

Table

1.1 List of Tables

Table 1: Infectious Disease Market, Australia, Revenue ($m), USD Constant, 2015-2020 17

Table 2: Infectious Disease Market, Australia, Revenue ($m), USD Constant, 2021-2025 19

Table 3: Chlamydia Trachomatis Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 22

Table 4: Chlamydia Trachomatis Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 22

Table 5: Clostridium difficile Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 24

Table 6: Clostridium difficile Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 24

Table 7: Cytomegalovirus (CMV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 26

Table 8: Cytomegalovirus (CMV) Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 26

Table 9: Hepatitis Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 28

Table 10: Hepatitis Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 28

Table 11: Human Immunodeficiency Virus (HIV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 30

Table 12: Human Immunodeficiency Virus (HIV) Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 31

Table 13: Human Papilloma Virus (HPV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 33

Table 14: Human Papilloma Virus (HPV) Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 33

Table 15: Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 35

Table 16: Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 35

Table 17: Mycobacterium Tuberculosis Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 37

Table 18: Mycobacterium Tuberculosis Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 37

Table 19: Neisseria Gonorrhoeae Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 39

Table 20: Neisseria Gonorrhoeae Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 39

Table 21: Treponema pallidum Tests Market, Australia, Revenue ($m), USD Constant, 2015-2020 41

Table 22: Treponema pallidum Tests Market, Australia, Revenue ($m), USD Constant, 2021-2025 42

Table 23: Infectious Disease Market, Australia, Volume (Units), 2015-2020 44

Table 24: Infectious Disease Market, Australia, Volume (Units), 2021-2025 46

Table 25: Chlamydia Trachomatis Tests Market, Australia, Volume (Units), 2015-2020 49

Table 26: Chlamydia Trachomatis Tests Market, Australia, Volume (Units), 2021-2025 49

Table 27: Clostridium difficile Tests Market, Australia, Volume (Units), 2015-2020 51

Table 28: Clostridium difficile Tests Market, Australia, Volume (Units), 2021-2025 52

Table 29: Cytomegalovirus (CMV) Tests Market, Australia, Volume (Units), 2015-2020 54

Table 30: Cytomegalovirus (CMV) Tests Market, Australia, Volume (Units), 2021-2025 54

Table 31: Hepatitis Tests Market, Australia, Volume (Units), 2015-2020 56

Table 32: Hepatitis Tests Market, Australia, Volume (Units), 2021-2025 56

Table 33: Human Immunodeficiency Virus (HIV) Tests Market, Australia, Volume (Units), 2015-2020 58

Table 34: Human Immunodeficiency Virus (HIV) Tests Market, Australia, Volume (Units), 2021-2025 59

Table 35: Human Papilloma Virus (HPV) Tests Market, Australia, Volume (Units), 2015-2020 61

Table 36: Human Papilloma Virus (HPV) Tests Market, Australia, Volume (Units), 2021-2025 61

Table 37: Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Volume (Units), 2015-2020 63

Table 38: Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Volume (Units), 2021-2025 63

Table 39: Mycobacterium Tuberculosis Tests Market, Australia, Volume (Units), 2015-2020 65

Table 40: Mycobacterium Tuberculosis Tests Market, Australia, Volume (Units), 2021-2025 65

Table 41: Neisseria Gonorrhoeae Tests Market, Australia, Volume (Units), 2015-2020 67

Table 42: Neisseria Gonorrhoeae Tests Market, Australia, Volume (Units), 2021-2025 67

Table 43: Treponema pallidum Tests Market, Australia, Volume (Units), 2015-2020 69

Table 44: Treponema pallidum Tests Market, Australia, Volume (Units), 2021-2025 70

Table 45: Infectious Disease Market, Australia, Average Price ($), 2015-2020 71

Table 46: Infectious Disease Market, Australia, Average Price ($), 2021-2025 74

Table 47: Infectious Disease Market, Australia, Distribution Share by Revenue ($m), USD Constant, 2018 77

Table 48: Infectious Disease Market, Australia, Company Share by Revenue ($m), USD Constant, 2018 79

Table 49: Infectious Disease Market Pipeline Products 83

Table 50: Genetic Signatures Raises USD1.7 Million in Share Purchase Plan 86

Table 51: Genetic Signatures to Raise USD13.4 Million in Second Tranche of Private Placement of Shares 87

Table 52: Genetic Signatures Raises USD10.4 Million in First Tranche of Private Placement of Shares 89

Table 53: Anteo Diagnostics Raises USD1.79 Million in Rights Offering 91

Table 54: Ellume Plans to Raise Funds in IPO of Shares 92

Table 55: SpeeDx Raises USD10 Million in Venture Financing 93

Table 56: Ellume Raises USD3.4 Million in Financing Round 94

Table 57: SpeeDx Raises Additional USD5 Million in Series A Financing 95

Table 58: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 113

Figures

1.2 List of Figures

Figure 1: Infectious Disease Market, Australia, Revenue ($m), USD Constant, 2015-2025 16

Figure 2: Chlamydia Trachomatis Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 21

Figure 3: Clostridium difficile Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 23

Figure 4: Cytomegalovirus (CMV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 25

Figure 5: Hepatitis Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 27

Figure 6: Human Immunodeficiency Virus (HIV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 29

Figure 7: Human Papilloma Virus (HPV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 32

Figure 8: Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 34

Figure 9: Mycobacterium Tuberculosis Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 36

Figure 10: Neisseria Gonorrhoeae Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 38

Figure 11: Treponema pallidum Tests Market, Australia, Revenue ($m), USD Constant, 2015-2025 40

Figure 12: Infectious Disease Market, Australia, Volume (Units), 2015-2025 43

Figure 13: Chlamydia Trachomatis Tests Market, Australia, Volume (Units), 2015-2025 48

Figure 14: Clostridium difficile Tests Market, Australia, Volume (Units), 2015-2025 50

Figure 15: Cytomegalovirus (CMV) Tests Market, Australia, Volume (Units), 2015-2025 53

Figure 16: Hepatitis Tests Market, Australia, Volume (Units), 2015-2025 55

Figure 17: Human Immunodeficiency Virus (HIV) Tests Market, Australia, Volume (Units), 2015-2025 57

Figure 18: Human Papilloma Virus (HPV) Tests Market, Australia, Volume (Units), 2015-2025 60

Figure 19: Human T-Lymphotropic Virus (HTLV) Tests Market, Australia, Volume (Units), 2015-2025 62

Figure 20: Mycobacterium Tuberculosis Tests Market, Australia, Volume (Units), 2015-2025 64

Figure 21: Neisseria Gonorrhoeae Tests Market, Australia, Volume (Units), 2015-2025 66

Figure 22: Treponema pallidum Tests Market, Australia, Volume (Units), 2015-2025 68

Figure 23: Infectious Disease Market, Australia, Company Share (%) 2018 78

Frequently asked questions

Australia Infectious Disease Market Outlook to 2025 standard reports
Currency USD
$4,995

Can be used by individual purchaser only

Most Popular
$9,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports
Medical Devices
New
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region…
$4,000 | March 2024
Medical Devices
New
PCR Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Medical Devices
New
Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Australia Infectious Disease Market Outlook to 2025 in real time.

  • Access a live Australia Infectious Disease Market Outlook to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more